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Abstract
Background: The first metatatarsophalangeal joint (1st MTP joint) is a common location for sonographic evidence
of urate deposition in people with gout and asymptomatic hyperuricaemia. However, it is unclear whether these
are related to clinically-assessed pain and function. This study aimed to determine the association between
ultrasound features and clinical characteristics of the 1st MTP joint in people with gout, asymptomatic
hyperuricaemia and age- and sex-matched normouricaemic individuals.
Methods: Twenty-three people with gout, 29 with asymptomatic hyperuricaemia and 34 with normouricaemia
participated in a cross-sectional study. No participant had clinical evidence of acute inflammatory arthritis at the
time of assessment. Four sonographic features at the 1st MTP joint were analysed: double contour sign, tophus,
bone erosion and synovitis. Clinical characteristics included in the analysis were 1st MTP joint pain, overall foot pain
and disability, 1st MTP joint temperature, 1st MTP joint range of motion and gait velocity. Statistical analyses
adjusted for the diagnostic group of the participant.
Results: After accounting for the diagnostic group, double contour sign was associated with higher foot pain and
disability scores (P < 0.001). Ultrasound tophus was associated with higher foot pain and disability scores (P < 0.001),
increased temperature (P = 0.005), and reduced walking velocity (P = 0.001). No associations were observed between
ultrasound synovitis or erosion and the clinical characteristics.
Conclusions: Ultrasound features of urate crystal deposition, rather than soft tissue inflammation or bone erosion,
are associated with clinical measures of foot-related functional impairment and disability even in the absence of
clinical evidence of current acute inflammatory arthritis. This association persisted regardless of the diagnosis of the
participant as having gout or asymptomatic hyperuricaemia.
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Background
Musculoskeletal ultrasonography has gained notable recog-
nition among imaging modalities used in the assessment of
gouty arthritis due to its ability to visualise not only soft tis-
sue inflammation and joint damage, but also monosodium
urate (MSU) crystals. Recent sonographic studies have
demonstrated MSU deposition and inflammation within
musculoskeletal structures in patients with gout even in
the absence of current symptoms of acute arthritis [1–3].
Furthermore, hyperuricaemic individuals, who have never
experienced an episode of acute arthritis, also demonstrate
subclinical deposition of MSU crystals on ultrasound
assessment [4–7]. The long-term relevance of ongoing
subclinical disease activity in these individuals is uncertain.
MSU crystal deposition primarily targets peripheral struc-
tures of the lower limbs and individuals with both gout and
asymptomatic hyperuricaemia present with high levels of
self-reported foot pain and disability when compared to
healthy people with normal urate levels [8]. Biomechanical-
based research has also shown that they demonstrate lower
limb functional impairments related to spatiotemporal
parameters of gait and plantar foot loading [9–11].
The first metatarsophalangeal joint (1st MTP joint),
which plays an important functional role during the pro-
pulsive phase of gait, is the most common joint affected in
people with gout. A recent meta-analysis estimated 73% of
people with gout experience symptoms of acute arthritis
at the 1st MTP joint at least once during the course of
their disease [12]. In addition, patients with gout report
persistent 1st MTP joint pain and exhibit local structural
and functional changes at this joint including reduced
muscular strength, limited joint motion and an increased
prevalence of musculoskeletal deformity [8].
Associations have been shown between imaging find-
ings and clinical measures of foot pain and function in
people with rheumatoid arthritis [13] and people with-
out arthritis with painful 1st MTP joints [14]. However,
it is unclear whether 1st MTP joint sonographic features
are related to clinical measures of structure, function
and pain in people with gout or asymptomatic hyperuri-
caemia, despite the important functional role of this
joint and its susceptibility to MSU deposition. This study
aimed to determine the association between sonographic
features and clinical characteristics of the 1st MTP joint
in people with gout, asymptomatic hyperuricaemia and
age- and sex-matched normouricaemic individuals.
Methods
We analysed data from a cross-sectional study examining
both ultrasound features and foot function in people with
gout, asymptomatic hyperuricaemia, and age- and sex-
matched normouricaemic controls [1, 8, 9]. This analysis
of the association between ultrasound findings and foot
pain and function was pre-specified in the study protocol.
Participants
Ethical approval for the study was obtained from the AUT
Ethics Committee (13/100). All participants provided writ-
ten informed consent prior to data collection. A total of
86 participants (gout n = 23, asymptomatic hyperuricae-
mia n = 29, and age- and sex-matched normouricaemic
controls n = 34) were included in the study. This sample
size was calculated from existing prevalence rates of the
double contour sign at the 1st MTP joint [2, 5, 15–17],
which provides approximately 80% power to detect a
difference between asymptomatic hyperuricaemia and
controls and 87% power to detect a difference between
gout and controls at a significance level of 5% against two-
side alternatives. Participants with gout were recruited
from Auckland District Health Board, New Zealand, using
a consecutive sampling technique. All participants with
gout fulfilled the 1977 preliminary American Rheumatism
Association (ARA) classification criteria for gout [18].
Participants without gout were recruited from Auckland
University of Technology (AUT) staff and underwent
serum urate capillary testing on the day of the study using
a Reflotron® Plus (Roche Diagnostics Ltd., New Zealand).
They were stratified into either the asymptomatic hyper-
uricaemic group (serum urate ≥ 6.9 mg/dL) or the nor-
mouricaemic control group (serum urate < 6.9 mgl/dL).
The three groups were age-and sex-matched. Participants
were excluded if they were aged under 20 years (to meet
the requirements of the AUT Ethics Committee); had a
history of other inflammatory arthritis; were experiencing
acute arthritis at the time of the study; had foot and/or
ankle surgery in the previous three months; had a history
of 1st MTP joint surgery; or lower limb amputation.
Demographic data were obtained from all participants in-
cluding age, gender, ethnicity, body mass index (BMI),
current medications and medical history. Additionally,
gout disease characteristics were documented for partici-
pants with gout including disease duration, flare history
and tophus presence.
Sonographic features
The ultrasound examination was performed at the AUT
Horizon Scanning Clinic by a single experienced musculo-
skeletal radiologist (BA) who was blinded to all clinical
features including gout status and serum urate results. A
Phillips iU22 diagnostic ultrasound machine (Bothell,
Washington, USA) with a 10 MHz, 55 mm linear array
transducer was used. All B-mode settings, including fre-
quency, focal zones, gain and depth were standardised
across participants. Bilateral 1st MTP joints were scanned
with participants positioned supine with legs extended. A
water-based gel was applied to the skin to optimise
transducer-skin contact and to provide an acoustic inter-
face. The dorsal, medial and plantar aspects of each joint
were scanned using a multi-planar technique, in which
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transverse and longitudinal planes were imaged. Each
joint was maximally dorsiflexed and plantarflexed by
the radiologist during scanning to ensure direct visual-
isation of the articular surface of the first metatarsal
head. A dynamic technique was adopted in which the
probe insonation angle was manipulated by the sonog-
rapher to reduce the occurrence of the cartilage inter-
face sign. Each joint was scanned in B-mode grey scale
and then using power Doppler. Power Doppler involved
the use of a standardised pulse repetition frequency of
400 to 500 Hz and low wall filters with the gain
adjusted to a level just below the disappearance of the
colour signs within the bony cortex [19, 20].
Two musculoskeletal radiologists (BA and RM) who
were blinded to all clinical features, including diagnostic
group status and serum urate results, and to each other’s
scores, independently reviewed the static images for the
presence of four ultrasound features: the double contour
sign, tophus, erosion and synovitis. The double contour
sign was defined as an abnormal hyperechoic band over
the superficial margin of the articular cartilage, independ-
ent of insonation [21]. Tophus was defined as a circum-
scribed, inhomogeneous, hyperechoic and/or hypoechoic
aggregation that may or may not generate a posterior
acoustic shadow and that may be surrounded by a small
anechoic rim [21]. Erosions were defined as intra-articular
discontinuity of the bone surface, visible in two perpen-
dicular planes [21]. Synovitis was defined as the presence
of the power Doppler signal (including both single and
confluent vessel signals) within the joint space [22]. For
the purpose of the inferential analyses, ultrasound features
were considered present only if scored as present by both
readers.
Clinical foot assessment
Both right and left 1st MTP joint pain over the past
week was assessed using 100 mm Visual Analogue Scales
(VAS) anchored with ‘no pain’ (0 mm) and ‘worst pain
imaginable’ (100 mm). Patient-reported overall foot pain
and disability was assessed using the 19-item Manches-
ter Foot Pain and Disability Index (MFPDI) [23]. Each
item was answered ‘none of the time’ (scored as 0), ‘on
some days’ (scored as 1) or ‘on most/every day(s)’
(scored as 2) in the past month and a total score out of
38 was summated for each participant.
Temperature of the 1st MTP joint was measured using
a DermaTemp 1001 (Exergen Corporation, Massachu-
setts), which is a hand-held infrared thermographic
scanner with an in-built sensor. Participants were given
adequate equilibration time in the room (thermostatic-
ally controlled at 22 °C ± 2 °C). Three temperature read-
ings were recorded from the dorsal aspect of the 1st
MTP joint for each foot, and the mean of the three trials
calculated for use in the inferential analyses.
Passive, non-weight-bearing 1st MTP joint dorsiflexion
range of motion (ROM) was measured using a hand-held
goniometer (Whitehall Manufacturing Ltd., California,
USA) in accordance with the procedure outlined by Hop-
son and McPoil [24]. Participants were positioned seated
with knees extended and the ankle in neutral. Lines were
drawn on the medial aspect of the foot along the sagittal bi-
sections of the first metatarsal and proximal phalanx. The
examiner applied a dorsiflexion force to the hallux until it
could no longer be passively moved into further extension.
The angle between the two bisection lines was measured
from the goniometer. Three repeated measurements of
right and left feet were taken and the mean for each
foot calculated for use in the inferential analyses.
Walking velocity (m/s) during level barefoot walking
was collected using the GAITRite system (CIR Systems,
Inc., New Jersey, US). The GAITRite is a 700 cm x
90 cm electronic walkway with an active sensor area of
610 cm long and 60 cm wide. The active area contains
23,040 embedded pressure-activated sensors with a
spatial resolution of 1.27 cm and a sampling rate of
120 Hz. All data was processed and stored by an IBM
compatible computer using GAITRite® gold, Version 3.2
b software. Participants were instructed to walk at their
own comfortable walking speed [25] from a point
100 cm before the walkway and finishing 100 cm past its
end to ensure that when they reached the walkway they
were walking at a normal speed and momentum. Three
trials of barefoot walking were recorded for each partici-
pant with adequate rest time between trials and the
mean of the three trials used for the inferential analyses.
Statistical analysis
All descriptive data were described as mean (SD) for
continuous data and frequency (%) for categorical data.
All clinical outcome measures were reviewed for nor-
mality using the residuals from a linear model. Mixed
linear regression models were used to determine the
univariate associations between the sonographic features
(independent variables) and clinical characteristics
(dependent variables) of the 1st MTP joint. The overall
models included the sonographic feature as a fixed effect
as well as the interaction effect between the sonographic
feature and diagnostic group. All models accounted for
repeated measures taken from right and left feet through
inclusion of a participant-specific random effect and
participant-nested random effect for foot-side were
added to the model. This analysis produces results iden-
tical to an analysis of measures averaged for each foot-
side that would allow for a between-foot-side correlation
and also allows for any reweighting required due to
missing values. Bonferroni-adjusted significance levels
were used for the inferential analyses (P < 0.01). Data
were analysed using IBM SPSS Statistics version 22.
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Table 1 Descriptive statistics for participant, sonographic and clinical characteristics
Variable Control Gout Asymptomatic
hyperuricaemia
N 34 23 29
Gender, male, n (%) 34 (100) 23 (100) 29 (100)
Age, years 58 (14) 58 (14) 58 (19)
Ethnicity, n (%) European 30 (88) European 14 (61) European 24 (83)
Maori 1 (3) Maori 1 (4) Maori 0 (0)
Pacific 0 (0) Pacific 4 (17) Pacific 3 (10)
Asian 3 (9) Asian 4 (17) Asian 2 (7)
BMI, kg/m2 25.0 (2.9) 30.8 (3.8)a 29.3 (5.9)a
Diuretic use, n (%) 4 (12) 3 (13) 7 (24)
NSAID use, n (%) 7 (21) 14 (61)a 11 (38)
Prednisone use, n (%) 0 (0) 5 (22) 0 (0)
Hypertension, n (%) 9 (26) 16 (70)a 16 (55)a
Cardiovascular disease, n (%) 1 (3) 6 (26)a 5 (17)
Diabetes, n (%) 2 (6) 4 (17) 1 (3)
Serum urate, mg/dl 5.4 (1.0) 5.9 (1.7) 7.7 (0.8)a
Disease duration, years - 18 (11) -
Number of acute flares in preceding 3 months - 1.4 (1.4) -
1MTP flares in preceding 3 months, n (%) - 6 (26) -
History of 1st MTP joint flares, n (%) - 19 (83) -
Presence of clinically-evident tophi at any site, n (%) - 17 (74) -
Presence of clinically-evident tophi at the 1st MTP joint, n (%)b - 6 (13) -
Urate lowering therapyb, n (%) - 22 (96) -
Microscopically-proven gout, n (%) - 6 (26) -
US double contour signb, n (%) 9 (13) 17 (37) 21 (36)
US tophusb, n (%) 0 (0) 6 (13) 0 (0)
US erosionb, n (%) 2 (3) 15 (33) 1 (2)
US synovitisb, n (%) 5 (7) 20 (44) 2 (3)
1st MTP joint pain VASb, mm 1.6 (4.0) 8.5 (15.6) 6.9 (15.1)
Manchester Foot Pain and Disability Index 1.8 (6.0) 13.4 (10.8) 3.4 (4.8)
1st MTP joint range of motionb, ° 77.6 (17.4) 59.0 (19.6) 76.5 (16.9)
1st MTP joint temperatureb, °C 25.3 (2.1) 27.4 (2.8) 26.1 (2.2)
Gait velocity, m/s 1.05 (0.19) 0.88 (0.17) 1.05 (0.24)
Values presented as mean (SD) unless otherwise indicated. aSignificantly different from control group (P < 0.05). bValues are based on joints (controls
= 68 joints; gout = 46 joints; asymptomatic hyperuricaemia = 58 joints). BMI body mass index, NSAID non-steroidal anti-inflammatory drugs, US ultra-
sound, VAS Visual Analogue Scale, o degrees
Table 2 Association between clinical characteristics and presence of the double contour sign
Least squares mean Diff. 95% CI for Diff. P
Present Absent Lower Upper
1st MTP joint Pain VAS, mm 3.4 7.0 3.5 −1.0 8.0 0.12
Manchester Foot Pain and Disability Index 10.1 4.8 −5.4 −7.8 −2.9 <0.001a
1st MTP joint range of motion,° 68.8 72.2 2.4 −3.2 8.1 0.40
1st MTP joint temperature, °C 26.8 26.0 −0.8 −1.5 0.1 0.018
Walking velocity, m/s 1.02 1.00 −0.02 −0.10 0.05 0.52
Results are presented adjusted for diagnostic group. aSignificantly different at Bonferroni-adjusted level of < 0.01. Diff. Difference in mean estimate between
presence and absence, CI Confidence Interval, 1st MTP joint first metatarsophalangeal joint, o degrees
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Results
All participants were men with a mean age of 58 years
and predominantly of European ethnicity (Table 1).
Participants with gout and asymptomatic hyperuricaemia
had significantly higher BMI compared to the controls
(P < 0.05). Participants with gout had a mean (SD) dis-
ease duration of 18 (11) years. Eighty-three percent had
a history of 1st MTP joint acute arthritis and 26% had
clinical evidence of 1st MTP joint tophi. Descriptive
statistics for the ultrasound features and clinical charac-
teristics are also presented in Table 1.
The distribution of residuals from the linear models
for all continuous outcome measures demonstrated suf-
ficient normality to carry out parametric testing. The
interaction effect between the sonographic feature and
diagnostic group was significant (P < 0.05) in the major-
ity of analyses (data not reported), indicating that associ-
ations between the ultrasound and clinical variables
were different across groups. After accounting for the
diagnostic group, presence of the double contour sign
was significantly associated with higher MFPDI scores
(P < 0.001) (Table 2). After accounting for the diagnostic
group presence of tophus was significantly associated
with higher MFPDI scores (P < 0.001), increased 1st
MTP joint temperature (P = 0.005) and reduced walking
velocity (P = 0.001) (Table 3). No associations were
observed between erosion and the clinical characteristics
(Table 4) or synovitis and the clinical characteristics
(Table 5).
Discussion
This study sought to identify the association between
sonographic features of urate deposition, bone erosion
and soft tissue inflammation at the 1st MTP joint and
clinically-assessed outcomes related to pain, structure
and function of the 1st MTP joint while accounting for
the diagnosis of the participant as having gout, asymp-
tomatic hyperuricaemia or normouricaemia.
Both sonographic features of MSU deposition, double
contour sign and tophus, were associated with increased
overall patient-reported foot pain and disability. Previous
research has shown that pain and functional limitations
related to the feet and lower limbs are a persistent finding
in people with gout and asymptomatic hyperuricaemia,
even in the absence of acute arthritis [8, 26, 27]. Our find-
ings indicate that urate deposition, rather than soft tissue
or bone changes, may be associated with foot-related pain
and disability. The lack of association between the double
contour sign and other clinical characteristics may be re-
lated to the overall low prevalence of the double contour
sign in the participants. This may be related to difficulty
in differentiating this sign from the normal cartilage inter-
face reflection in addition to the moderate inter-observer
reliability [1].
The presence of tophus at the 1st MTP joint was also
associated with increased local temperature, which is a
clinical feature of underlying inflammation. The presence
of larger urate deposits, in the form of tophi, may repre-
sent a more progressive disease and an environment more
Table 3 Association between clinical characteristics and presence of tophus
Least squares mean Diff. 95% CI for Diff. P
Present Absent Lower Upper
1st MTP joint Pain VAS, mm 2.4 6.0 3.6 −7.0 14.3 0.50
Manchester Foot Pain and Disability Index 19.8 5.9 −13.9 −19.7 −8.1 <0.001a
1st MTP joint range of motion, ° 55.1 71.2 16.1 2.4 29.7 0.021
1st MTP joint temperature, °C 28.6 26.2 −2.3 −3.9, −0.7 0.005a
Walking velocity, m/s 0.88 1.00 0.11 0.05 0.18 0.001a
Results are presented adjusted for diagnostic group. aSignificantly different at Bonferroni-adjusted level of < 0.01. Diff. Difference in mean estimate between
presence and absence, CI Confidence Interval, 1st MTP joint first metatarsophalangeal joint, o degrees
Table 4 Association between clinical characteristics and presence of erosion
Least squares mean Diff. 95% CI for Diff. P
Present Absent Lower Upper
1st MTP joint Pain VAS, mm 3.1 6.3 3.2 −6.0 12.4 0.49
Manchester Foot Pain and Disability Index 6.6 5.6 −1.0 −6.9 4.9 0.75
1st MTP joint range of motion, ° 66.2 71.2 5.0 −4.8 14.8 0.32
1st MTP joint temperature, °C 25.1 26.2 1.1 0.1 2.1 0.040
Walking velocity, m/s 0.95 1.00 0.05 −0.11 0.21 0.53
Results are presented adjusted for diagnostic group. Diff. Difference in mean estimate between presence and absence, CI Confidence Interval, 1st MTP joint first
metatarsophalangeal joint, o degrees
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prone to chronic inflammation, and therefore increased
temperature, as a result of continuous mechanical stress
in the joint during gait. In contrast, no relationship was
observed between synovitis (a direct measure of increased
soft tissue vascularisation) and increased temperature. It
may be that participants with synovitis in the current
study had only a mild Doppler signal [1], which may not
have been severe enough to be seen in clinical thermal
variations. It may be that the relationship between syno-
vitis and temperature would be more pronounced in pa-
tients experiencing current acute flares, who experience a
higher prevalence of more prominent Doppler signal [28].
This is consistent with studies in rheumatoid arthritis,
which have detected sonographic evidence of synovitis
despite the absence of any clinical features of inflamma-
tion [29–32].
The reduction in walking velocity in those with 1st
MTP joint tophus may be a result of the inability to
achieve the required 65° of dorsiflexion at the joint ne-
cessary for efficient propulsion in combination with
reduced 1st MTP joint plantarflexion strength and foot
pain [8]. This may support previously proposed hypoth-
eses that altered walking patterns adopted by people
with gout are related to pain-avoidance strategies and
inefficient 1st MTP joint function [9–11].
The findings from this study should be considered in
light of a number of limitations. Firstly, recruitment of
participants was undertaken prior to publication of the
2015 ACR/EULAR classification criteria for gout [33]
and the majority of the participants with gout were clas-
sified based on the 1977 ACR clinical criteria, which has
limited specificity [34]. Participants with normouricae-
mia and hyperuricaemia were classified based on a single
measure of serum urate, which may have reduced accur-
acy compared with multiple measurements over a longer
time period. The sampling technique used in the current
study resulted in all male participants, meaning the re-
sults may not be generalisable to both genders. The
adoption of a higher frequency transducer during scan-
ning may have enhanced the ultrasound findings. The
cross-sectional design of the study limits the ability to
determine whether sonographic features at the 1st MTP
joint preceded or were a consequence of the clinical
characteristics. Finally, concomitant osteoarthritis, which
was not assessed in the current study, is highly prevalent
at the 1MTP in people with gout [35], and may contrib-
ute to their functional impairment and disability. The
current study was limited to sonographic assessment of
the 1st MTP joint, and further assessment of other foot
and ankle structures for urate deposition, soft tissue and
osseous changes, may provide further insight into the
impact of sonographic features on overall foot-related
pain and disability. Additionally, further longitudinal re-
search may explore the role of foot and ankle structure
and function in predicting crystal deposition, inflamma-
tion and osseous erosion in individuals with asymptom-
atic hyperuricaemia.
Conclusions
In conclusion, this study has shown that sonographic
features of MSU deposition, rather than soft tissue in-
flammation or bone erosion, are associated with clinic-
ally evident foot-related pain, impairment and functional
disability. This may explain why these individuals with
asymptomatic hyperuricaemia, who lacked sonographic
features of soft tissue and bone involvement at the 1st
MTP joint [1], still presented with high levels of foot
pain and disability [8] and exhibited gait impairments
[9] when compared with normouricaemic individuals.
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